Search Results for ""drugs for""
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for "drugs for". Results 2071 to 2080 of 2680 total matches.

Treatment of Clostridium Difficile Diarrhea

   
The Medical Letter on Drugs and Therapeutics • Oct 20, 1989  (Issue 803)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
The gram-positive bacillus Clostridium difficile is the most common identifiable cause of antibiotic-associated diarrhea and pseudomembranous colitis (R Fekety in GL Mandell et al, eds, Principles and Practice of Infectious Diseases, 3rd ed, New York:Churchill Livingstone, 1990, page 863). C. difficile colitis usually develops during or soon after antibiotic treatment. Virtually any antimicrobial agent can cause the disorder, but clindamycin, ampicillin and the cephalosporins have been implicated most frequently. Pseudomembranous colitis was recently reported in five patients who had ...
Med Lett Drugs Ther. 1989 Oct 20;31(803):94-5 |  Show IntroductionHide Introduction

Metipranolol: A New Beta-blocker For Glaucoma

   
The Medical Letter on Drugs and Therapeutics • Oct 05, 1990  (Issue 828)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Metipranolol hydrocholride 0.3% (OptiPranolol - Bausch & Lomb), a nonselective beta-adrenergic receptor blocking drug, was recently marketed of ophthalmic use to decrease intraolular pressure in ocular hypertension or chronic open-angle glaucoma. Beta-blockers available in the USA for treatment of glaucoma are listed in this article.
Med Lett Drugs Ther. 1990 Oct 5;32(828):91-2 |  Show IntroductionHide Introduction

Aerosolized Deoxyribonuclease for Cystic Fibrosis

   
The Medical Letter on Drugs and Therapeutics • Apr 15, 1994  (Issue 920)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Recombinant human deoxyribonuclease I (rhDNase; dornase alfa; Pulmozyme - Genentech), an enzyme that hydrolyzes extracellular DNA, is now available as a purified solution to decrease the viscosity of sputum in patients with cystic fibrosis. It requires a nebulizer to produce an aerosol mist for inhalation.
Med Lett Drugs Ther. 1994 Apr 15;36(920):34-5 |  Show IntroductionHide Introduction

An ACE inhibitor after a Myocardial Infarction

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 1994  (Issue 928)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
The US Food and Drug Administration has approved use of the angiotensin-converting enzyme (ACE) inhibitor captopril (Capoten) for patients with left ventricular dysfunction after a myocardial infarction. ACE inhibitors, widely used for treatment of hypertension, in recent years have also been used for treatment of heart failure (Medical Letter, 35:40, 1993).
Med Lett Drugs Ther. 1994 Aug 5;36(928):69-70 |  Show IntroductionHide Introduction

Valacyclovir

   
The Medical Letter on Drugs and Therapeutics • Jan 05, 1996  (Issue 965)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Valacyclovir (Valtrex - Glaxo Wellcome), an L- valyl ester of acyclovir (Zovirax), has been approved by the US Food and Drug Administration (FDA) for oral treatment of herpes zoster (shingles) in immunocompetent adults. Famciclovir (Famvir - Medical Letter, 36:97, 1994) is also available for this indication.
Med Lett Drugs Ther. 1996 Jan 5;38(965):3-4 |  Show IntroductionHide Introduction

Hyaluronan Injections for Osteoarthritis of the Knee

   
The Medical Letter on Drugs and Therapeutics • Jul 03, 1998  (Issue 1030)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Sodium hyaluronate (Hyalgan - Sanofi) and hylan G-F 20 (Synvisc - Wyeth- Ayerst) have been approved by the FDA for intra-articular injections in patients with knee pain due to osteoarthritis. Hylan G-F 20 is a cross-linked derivative of hyaluronic acid with a higher molecular weight than sodium hyaluronate. 'Hyaluronan' refers to either the acid or its salt.
Med Lett Drugs Ther. 1998 Jul 3;40(1030):69-70 |  Show IntroductionHide Introduction

Tamoxifen for Breast Cancer Prevention

   
The Medical Letter on Drugs and Therapeutics • Jan 01, 1999  (Issue 1043)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Tamoxifen, anti-estrogen used for many years in the treatment of breast cancer, has now been approved by the FDA for reducing the incidence of breast cancer in women at increased risk of developing the disease.
Med Lett Drugs Ther. 1999 Jan 1;41(1043):1-2 |  Show IntroductionHide Introduction

Hormone Replacement Therapy

   
The Medical Letter on Drugs and Therapeutics • Sep 02, 2002  (Issue 1138)
The Medical Letter  On Drugs and Therapeutics www.medicalletter.org Published by The Medical ...
The results of a large randomized controlled trial of estrogen plus a progestin to prevent heart disease in postmenopausal women were recently reported (Writing Group for the Women's Health Initiative Investigators, JAMA 2002; 288:321).
Med Lett Drugs Ther. 2002 Sep 2;44(1138):78 |  Show IntroductionHide Introduction

Are SSRIs Safe for Children?

   
The Medical Letter on Drugs and Therapeutics • Jul 07, 2003  (Issue 1160)
The Medical Letter  On Drugs and Therapeutics www.medicalletter.org Published by The Medical ...
A "Dear Colleague" letter from the UK's Committee on Safety of Medicines advised physicians, on the basis of unpublished data, not to use paroxetine (Paxil in the US; Seroxat in the UK) to treat children and adolescents with depression because of possible increased risk of suicidal behavior. This review describes the efficacy and safety of SSRIs in children.
Med Lett Drugs Ther. 2003 Jul 7;45(1160):53-4 |  Show IntroductionHide Introduction

In Brief: Calcium and Vitamin D Supplements

   
The Medical Letter on Drugs and Therapeutics • Jul 31, 2006  (Issue 1240)
Letter ® On Drugs and Therapeutics Volume 48 (Issue 1240) July 31, 2006 www.medicalletter.org ...
The results of a randomized, placebo-controlled trial of calcium and vitamin D supplements in more than 36,000 postmenopausal women, conducted as part of the Women’s Health Initiative (RD Jackson et al. N Engl J Med 2006; 354:669), have been misinterpreted by some patients to mean that they should stop taking such supplements.At the time of recruitment, the participants in this study had an average daily calcium intake of 1100-1200 mg. They were randomized to take either 1000 mg of calcium carbonate plus 400 IU of vitamin D3 or a placebo for an average of 7 years. Both groups were permitted...
Med Lett Drugs Ther. 2006 Jul 31;48(1240):61 |  Show IntroductionHide Introduction